Optimizing hormonal therapy for advanced and recurrent endometrial cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The PROMOTE study focuses on improving the use of hormonal therapy in patients with advanced and recurrent endometrial cancer by analyzing tumor tissue collected before treatment. It addresses the lack of consensus and quality data regarding patient selection and predictive biomarkers for hormonal treatment. This observational study aims to refine clinical criteria for selecting patients who may benefit from hormonal therapy, which is generally better tolerated than chemotherapy. Given the increasing incidence of endometrial cancer, especially among elderly women, this study seeks to provide more effective and less aggressive treatment options.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Advanced stage (FIGO stage III and IV) and recurrent endometrial cancer
* All histologic types of endometrial carcinoma
* Planned treatment with any type of hormonal therapy
* Biopsy taken within 120 days prior to start of hormonal therapy with no intercurrent therapy between biopsy and start of hormonal therapy.

Exclusion Criteria:

* Adjuvant hormonal therapy started following complete resection of endometrial carcinoma
* Synchronous use of hormonal therapy for other indications
* Endometrial sarcoma or endometrial stroma cell sarcoma

Where it's running

• Radboudumc
  Nijmegen, Netherlands Recruiting

Study contacts

• Principal investigator: Hanny Pijnenborg, MD PhD — Radboud University Medical Center
• Study coordinator: Maartje Luijten, MD
• Email: Maartje.luijten@radboudumc.nl
• Phone: +31243616683

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Pelvic ultra-hypofractionated radiotherapy after surgery for high-risk endometrial cancer

  This trial tests whether giving 27.5 Gy in five sessions of pelvic radiotherapy after surgery is safe and feasible for high-risk endometrial cancer patients.

  Recruiting Instituto de Investigación Sanitaria Aragón · Zaragoza, Zaragoza · NCT07779109

• OPB-201 therapy for recurrent endometrial and platinum-resistant ovarian cancer

  A one-time treatment with a patient’s own T cells engineered to target PRAME is being tested to see if it is safe and what dose works best for adults with recurrent endometrial cancer or platinum-resistant ovarian cancer.

  Recruiting at 5 sites Phase 1 Outpace Bio, Inc. · San Francisco, California and 4 other locations · NCT07664735

• Exploring personalized treatment for recurrent gynecological cancers

  This study is testing if using genetic information to guide treatment can help improve outcomes for people with recurrent ovarian, cervical, or endometrial cancer.

  Recruiting at 2 sites Sun Yat-sen University · Guangzhou, Guangdong and 1 other locations · NCT06781151

• CAR-NK cell therapy for advanced solid tumors

  This study is testing a new treatment using specially modified immune cells to see if they can help people with advanced solid tumors like ovarian and testis cancers.

  Recruiting Phase 1 Second Affiliated Hospital of Guangzhou Medical University · Guangzhou, Guangdong · NCT05410717

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.